EP Patent

EP3454662A1 — Thermal-stable whipped formulations

Assigned to Bayer Healthcare LLC · Expires 2019-03-20 · 7y expired

What this patent protects

The present disclosure relates to, inter alia , a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first prop…

USPTO Abstract

The present disclosure relates to, inter alia , a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia , a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3454662A1
Jurisdiction
EP
Classification
Expires
2019-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Healthcare LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.